Rifampin plus Pyrazinamide for Treatment of Latent Tuberculosis Infection (LTBI)
August 12, 2003
Audience: Infectious Disease and other healthcare professionals
The Centers for Disease Control and Prevention (CDC) notified healthcare professionals of revised recommendations against the use of rifampin plus pyrazinamide for treatment of latent tuberculosis infection, due to high rates of hospitalization and death from liver injury associated with the combined use of these drugs.[August 8, 2003 Letter - CDC]
[August 8, 2003 MMWR Article - CDC]
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.